FDA has accepted and granted priority review for a new supplemental Biologics License Application for Keytruda as monotherapy for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
